Lyell Immunopharma (LYEL) Asset Writedowns and Impairment (2021 - 2025)

Lyell Immunopharma (LYEL) has 4 years of Asset Writedowns and Impairment data on file, last reported at -$43000.0 in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 100.08% year-over-year to -$43000.0; the trailing twelve-month figure through Dec 2025 stood at $52.7 million (up 13.73% YoY), and the FY2025 full-year result was $1.4 million, down 97.27% from the prior year.
• Asset Writedowns and Impairment fell to -$43000.0 in Q4 2025, from $1.4 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $51.3 million in Q4 2024 to a low of -$5.0 million in Q4 2022.
• A 4-year average of $14.8 million and a median of $3.2 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment sank 113.74% in 2022 and slumped 100.08% in 2025, its largest moves.
• Tracing LYEL's Asset Writedowns and Impairment over 4 years: stood at $36.4 million in 2021, then slumped by 113.74% to -$5.0 million in 2022, then soared by 1125.94% to $51.3 million in 2024, then plunged by 100.08% to -$43000.0 in 2025.
• Business Quant data shows LYEL's Asset Writedowns and Impairment at -$43000.0 in Q4 2025, $1.4 million in Q2 2025, and $51.3 million in Q4 2024.